Position history for BAKER BROS. ADVISORS LP's holdings in CRINETICS PHARMACEUTICALS IN
BAKER BROS. ADVISORS LP holds 2.4M shares of CRNX (CRINETICS PHARMACEUTICALS IN), worth $85.4M as of 2026-Q1. The position was increased (+42.6% shares). CRNX represents 0.5% of BAKER BROS. ADVISORS LP's portfolio.
Current Value
$85.4M
Current Shares
2.4M
Total Value Change
+$80.8M
Total Shares Change
+2.2M
Other major holders of CRNX: BNP PARIBAS FINANCIAL MARKETS, FMR LLC, UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC
Increased |
| 2.4M |
+42.6% |
| $85.4M |
| 0.5% |
| $40.12 |
48 |
| 2025-Q4 | Increased | 1.6M | +488.9% | $76.8M | 0.4% | $47.39 | 57 |
| 2025-Q3 | Unchanged | 280,000 | 0.0% | $11.7M | 0.1% | $43.51 | 0 |
| 2025-Q2 | New | 280,000 | - | $8.1M | 0.1% | $29.96 | 38 |
| 2024-Q4 | Exited | 0 | -100.0% | $0 | 0.0% | $50.67 | 0 |
| 2024-Q3 | Unchanged | 103,927 | 0.0% | $5.3M | 0.1% | $50.75 | 0 |
| 2024-Q2 | New | 103,927 | - | $4.7M | 0.1% | $44.79 | 37 |